Literature DB >> 18338194

Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke.

M Uyttenboogaart1, M W Koch, K Koopman, P C Vroomen, G J Luijckx, J De Keyser.   

Abstract

BACKGROUND: Low cholesterol levels have been associated with an increased risk of haemorrhagic stroke. This study investigated whether lipid levels or prior statin use influence outcome in patients with acute ischaemic stroke treated with IV thrombolysis.
METHODS: The relation between admission lipid levels or statin use and both the development of symptomatic intracerebral haemorrhage (sICH) and 3-months functional outcome was assessed in a prospective hospital-based stroke registry comprising 252 patients treated with IV tissue plasminogen activator (tPA). The fasting status of the patients was unknown. Favourable outcome at 3 months was defined as a modified Rankin scale score <or= 2. Logistic regression analysis was performed with adjustment for possible confounders.
RESULTS: Low density lipoprotein (LDL), total cholesterol levels, and statin use were not associated with sICH. Mean triglyceride levels were significantly higher (2.5 mmol/L vs 1.8 mmol/L, p = 0.02) and high density lipoprotein (HDL) was significantly lower (1.0 mmol/L vs 1.2 mmol/L, p = 0.03) in patients with sICH than in patients without sICH. Multivariable analysis showed that higher triglyceride levels were independently associated with sICH (OR 2.16 per mmol/ L increase, 95 % CI 1.20-3.91, p = 0.01). There was no relation between any of the lipid levels or statin use and functional outcome at 3 months.
CONCLUSIONS: High admission triglyceride levels were independently associated with a higher risk of sICH, but were not associated with a reduced chance of a favourable functional outcome at 3 months. Total cholesterol levels, LDL levels and statin use had no influence on both the occurrence of sICH or functional outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338194     DOI: 10.1007/s00415-008-0797-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

1.  Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association.

Authors:  Harold Adams; Robert Adams; Gregory Del Zoppo; Larry B Goldstein
Journal:  Stroke       Date:  2005-04       Impact factor: 7.914

2.  Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke.

Authors:  M Uyttenboogaart; P C A J Vroomen; R E Stewart; J De Keyser; G J Luijckx
Journal:  J Neurol Sci       Date:  2007-01-25       Impact factor: 3.181

3.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

4.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

Authors:  S M Haffner; M P Stern; H P Hazuda; B D Mitchell; J K Patterson
Journal:  JAMA       Date:  1990-06-06       Impact factor: 56.272

5.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

6.  Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis.

Authors:  O Y Bang; J L Saver; D S Liebeskind; S Starkman; P Villablanca; N Salamon; B Buck; L Ali; L Restrepo; F Vinuela; G Duckwiler; R Jahan; T Razinia; B Ovbiagele
Journal:  Neurology       Date:  2006-12-20       Impact factor: 9.910

7.  Prior use of antithrombotic agents and neurological functional outcome at discharge in patients with ischemic stroke.

Authors:  M Paciaroni; G Agnelli; V Caso; M Venti; A Alberti; P Milia; G Silvestrelli; S Biagini
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

8.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

9.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

10.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

View more
  18 in total

1.  Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial.

Authors:  Wan-Yong Yang; Yu-Feng Li; Zi-Ran Wang; Tian-Xia Yu; Dong-Juan Xu; Nan Yang; Xiao-Yuan Niu; Xue-Li Cai; Wen-Yan Zhuo; Xue-Mei Wu; Min Yan; Jun-Shan Zhou; Hao-Wen Zhang; Zhi-Gang Liang; Wen-Jun Wu; Jian-Hua Cheng; Li-An Huang; Yu-Sheng Zhang; Ying Guan; Ze-Feng Tan; Dan Lu; Niu He; Da-Wei Dong; Hui-Li Zhu; Bing Yang; Qing-Yu Shen; An-Ding Xu
Journal:  J Neurol       Date:  2021-02-08       Impact factor: 4.849

2.  Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.

Authors:  Sergi Martinez-Ramirez; Raquel Delgado-Mederos; Rebeca Marín; Marc Suárez-Calvet; María Pilar Sáinz; Aída Alejaldre; Ángela Vidal-Jordana; Josep Lluís Martí-Vilalta; Joan Martí-Fàbregas
Journal:  J Neurol       Date:  2011-06-18       Impact factor: 4.849

3.  Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.

Authors:  Paul A Lapchak; Moon Ku Han
Journal:  Brain Res       Date:  2010-05-19       Impact factor: 3.252

Review 4.  Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review.

Authors:  Nazeeha Hasan; Peter McColgan; Paul Bentley; Robert J Edwards; Pankaj Sharma
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

5.  Statin, cholesterol, and sICH after acute ischemic stroke: systematic review and meta-analysis.

Authors:  Changhong Tan; Xi Liu; Lijuan Mo; Xin Wei; Wuxue Peng; Hui Wang; Wen Zhou; Jin Jiang; Yangmei Chen; Lifen Chen
Journal:  Neurol Sci       Date:  2019-07-02       Impact factor: 3.307

Review 6.  The role of cholesterol and statins in stroke.

Authors:  Babak B Navi; Alan Z Segal
Journal:  Curr Cardiol Rep       Date:  2009-01       Impact factor: 2.931

Review 7.  Statins in Acute Ischemic Stroke: A Systematic Review.

Authors:  Keun-Sik Hong; Ji Sung Lee
Journal:  J Stroke       Date:  2015-09-30       Impact factor: 6.967

8.  Clinical factors associated with statins prescription in acute ischemic stroke patients: findings from the Lombardia Stroke Registry.

Authors:  Isabella Canavero; Anna Cavallini; Patrizia Perrone; Mauro Magoni; Lucia Sacchi; Silvana Quaglini; Giordano Lanzola; Giuseppe Micieli
Journal:  BMC Neurol       Date:  2014-03-21       Impact factor: 2.474

9.  Influence of lipid profiles on the risk of hemorrhagic transformation after ischemic stroke: systematic review.

Authors:  Katiuscia Nardi; Didier Leys; Paolo Eusebi; Charlotte Cordonnier; Sophie Gautier; Hilde Hénon; Régis Bordet
Journal:  Cerebrovasc Dis Extra       Date:  2011-12-29

Review 10.  Overcoming Challenges With Statin Therapy.

Authors:  J David Spence; George K Dresser
Journal:  J Am Heart Assoc       Date:  2016-01-27       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.